|MDACC Study No:||2012-0734 (clinicaltrials.gov NCT No: NCT01807598)|
|Title:||A study of brentuximab vedotin (SGN-35) in CD30-positive systemic mastocytosis +/- an associated hematological clonal |
non-mast cell lineage disease (AHNMD)
|Principal Investigator:||Srdan Verstovsek|
|Study Description:||The goal of this clinical research study is to learn if the study drug Adcetris |
(brentuximab vedotin) can help to control SM. The safety of this drug will
also be studied.
Brentuximab vedotin is designed to find a certain protein (CD30) on cancer
cells and bind to it. This may kill the cancer cells.